Dasiglucagon
A ready-to-use glucagon analogue for emergency rescue from severe low blood sugar
Dasiglucagon is a glucagon analogue that stays stable in solution, so it can be injected straight from an autoinjector in an emergency. Approved as Zegalogue in 2021 for severe hypoglycaemia; Drugs@FDA now lists both presentations as discontinued.
What is it?
Severe hypoglycaemia, blood sugar low enough that a person needs help to recover, is the most feared acute complication of insulin treatment. The standard rescue was glucagon, which releases glucose stored in the liver, but native glucagon is unstable in liquid, so older emergency kits had to be mixed from a powder in the moment.
Dasiglucagon was engineered to stay stable in solution, so the dose is ready to inject. In phase 3 trials in adults and children with type 1 diabetes, it raised blood sugar within a median of about 10 minutes, as fast as reconstituted glucagon. It was approved as Zegalogue in March 2021; as of October 2, 2026, Drugs@FDA lists both Zegalogue presentations as discontinued.
Beyond diabetes rescue, it has been studied as a continuous infusion in congenital hyperinsulinism, a rare condition in infants and children, and as a small self-injected dose for low blood sugar after gastric bypass. Neither is an approved use.
At a Glance
Every value in this table is printed from the Grey Peptides dataset, the same record the compound explorer and comparison tool read, so the three can never disagree.
Educational information, not medical advice. The doses on this page come from approved labels, published studies and, where no study exists, amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.
Half-Life: How Much Remains
The dataset records a half-life of about 30 minutes after an injection under the skin for Dasiglucagon. After each half-life, half of what was in the circulation is gone, so about 3% remains after five. Real clearance varies with the person, the dose, the route and kidney or liver function; this is arithmetic on a published figure, not a dosing tool.
Published Research
The studies behind dasiglucagon, read from their PubMed abstracts.
Phase 3 in adults with type 1 diabetes
In 170 adults during insulin-induced hypoglycaemia, 0.6 mg dasiglucagon restored blood sugar in a median 10 minutes against 40 on placebo and 12 on reconstituted glucagon; 99% recovered within 15 minutes. Nausea and vomiting were the commonest effects.
Phase 3 in children aged 6 to 17
In 42 children and adolescents, median recovery was 10 minutes on dasiglucagon against 30 on placebo, and every child on dasiglucagon or glucagon recovered within 20 minutes, against 2 of 11 on placebo.
Pooled safety and efficacy
Across placebo-controlled trials there were no serious adverse events, withdrawals or deaths; treatment-related nausea affected 56.5% and vomiting 24.6%. Median recovery was 10 minutes against 12 on glucagon and 40 on placebo.
Congenital hyperinsulinism, children
In 32 children aged 0.6 to 10.9 years, adding a dasiglucagon infusion did not significantly cut finger-prick-detected hypoglycaemia (the primary end point), but a post hoc analysis found 43% less hypoglycaemia on continuous glucose monitoring.
Congenital hyperinsulinism, infants
In 12 infants dependent on intravenous glucose, dasiglucagon cut the glucose infusion rate needed to keep blood sugar normal to 4.3 mg/kg/min against 9.5 on placebo over 48 hours.
Low blood sugar after gastric bypass
In 24 people with post-bariatric hypoglycaemia, four weeks of self-injected 120 µg doses cut time below 3.0 mmol/L by 54% against placebo, and corrected 97.3% of episodes within 15 minutes against 29.1%.
Side Effects & Contraindications
Reported Side Effects
From the studies above.
Contraindications & Cautions
Warnings from the Zegalogue label (DailyMed, effective January 1, 2023).
Legal Status
Dasiglucagon was approved in the US as Zegalogue; Drugs@FDA now lists it as discontinued.
Frequently Asked Questions
?What is dasiglucagon?
A glucagon analogue that stays stable in liquid, approved as Zegalogue in 2021 for severe hypoglycaemia in people with diabetes aged 6 and older.
?How fast does it work?
In phase 3 trials it raised blood sugar in a median of about 10 minutes, similar to reconstituted glucagon and much faster than placebo.
?Is Zegalogue still available?
As of October 2, 2026, Drugs@FDA lists both Zegalogue presentations as discontinued, although a label remains on DailyMed.
References
- [fda] US FDA, Drugs@FDA (openFDA): ZEGALOGUE and ZEGALOGUE (AUTOINJECTOR) (dasiglucagon), NDA 214231, original approval March 22, 2021; marketing status Discontinued. Read October 2, 2026.
- [fda-pi] FDA. Zegalogue (dasiglucagon) injection US prescribing information (DailyMed set 14704879-872c-4967-8779-04a3bbdfb4e6, effective January 1, 2023). Read October 2, 2026.
- [clinical-trial] Pieber TR, et al. "Dasiglucagon-A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia: Results of Phase 3 Randomized Double-Blind Clinical Trial." Diabetes Care, 2021;44(6):1361-1367. PMID: 35239971.
- [clinical-trial] Battelino T, et al. "Dasiglucagon, a next-generation ready-to-use glucagon analog, for treatment of severe hypoglycemia in children and adolescents with type 1 diabetes: Results of a phase 3, randomized controlled trial." Pediatr Diabetes, 2021;22(5):734-741. PMID: 33934456.
- [pubmed] Heller S, et al. "Integrated safety and efficacy analysis of dasiglucagon for the treatment of severe hypoglycaemia in individuals with type 1 diabetes." Diabetes Obes Metab, 2023;25(5):1351-1360. PMID: 36692230.
- [clinical-trial] Thornton PS, et al. "Dasiglucagon for the Treatment of Congenital Hyperinsulinism: A Randomized Phase 3 Trial in Infants and Children." J Clin Endocrinol Metab, 2024;109(4):1071-1079. PMID: 37930757.
- [clinical-trial] De Leon DD, et al. "Dasiglucagon in Children With Congenital Hyperinsulinism Up to 1 Year of Age: Results From a Randomized Clinical Trial." J Clin Endocrinol Metab, 2025;110(8):e2674-e2681. PMID: 39584500.
- [clinical-trial] Nielsen CK, et al. "Dasiglucagon Treatment for Postprandial Hypoglycemia After Gastric Bypass: A Randomized, Double-Blind, Placebo-Controlled Trial." Diabetes Care, 2023;46(12):2208-2217. PMID: 37819999.
Sources & Citations
Studies were read from their PubMed records; regulatory sources are listed below, read October 2, 2026.
Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Consult a licensed healthcare provider before making health decisions.